Key result
Adenoviral SMN2-antisense U7 snRNA boosts exon 7 inclusion by ~82% and restores SMN protein in SMA fibroblasts.
Why the study?
Spinal Muscular Atrophy is caused by SMN1 gene mutations with SMN2 producing low SMN protein due to exon 7 skipping, necessitating strategies to correct SMN2 splicing.
Do Adenovirus type 5-derived vectors expressing SMN2-antisense U7 snRNA oligonucleotides increase SMN protein expression in SMA type I-derived patient fibroblasts?
Do Adenovirus type 5-derived vectors expressing SMN2-antisense U7 snRNA oligonucleotides increase SMN protein expression in SMA type I-derived patient fibroblasts?
Adenovirus type 5-derived vectors delivering U7 antisense oligonucleotides can efficiently restore full-length SMN protein in SMA type I fibroblasts, suggesting a potential therapeutic approach for Spinal Muscular Atrophy.
Antisense U7 snRNA adenoviral delivery may restore SMN2 splicing in SMA models; leaves open clinical translation pending further validation.
BACKGROUND: Spinal Muscular Atrophy (SMA) is an autosomal recessive disease that leads to specific loss of motor neurons. It is caused by deletions or mutations of the survival of motor neuron 1 gene (SMN1). The remaining copy of the gene, SMN2, generates only low levels of the SMN protein due to a mutation in SMN2 exon 7 that leads to exon skipping. METHODOLOGY/PRINCIPAL FINDINGS: To correct SMN2 splicing, we use Adenovirus type 5-derived vectors to express SMN2-antisense U7 snRNA oligonucleotides targeting the SMN intron 7/exon 8 junction. Infection of SMA type I-derived patient fibroblasts with these vectors resulted in increased levels of exon 7 inclusion, upregulating the expression of SMN to similar levels as in non-SMA control cells. CONCLUSIONS/SIGNIFICANCE: These results show that Adenovirus type 5-derived vectors delivering U7 antisense oligonucleotides can efficiently restore full-length SMN protein and suggest that the viral vector-mediated oligonucleotide application may be a suitable therapeutic approach to counteract SMA.
No takes yet. Share an insight, caveat, or question.
Geib et al. (2009) studied Spinal Muscular Atrophy. Adenovirus type 5-derived vectors expressing SMN2-antisense U7 snRNA oligonucleotides vs. Control vectors (SmOpt, GFP) or uninfected cells was evaluated on Exon 7 inclusion levels (p=≤0.005). Adenovirus type 5-derived vectors expressing SMN2-antisense U7 snRNA oligonucleotides increased SMN2 exon 7 inclusion from 33% to 60% (p≤0.005) and restored full-length SMN protein levels in SMA type I fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: